. Author manuscript; available in PMC: 2009 Feb 1.

Published in final edited form as: Am J Hypertens. 2008 Jun 19;21(8):910–916. doi: 10.1038/ajh.2008.213

Table 1.

Descriptive Characteristics of Participants at Baseline

	African-Americans (N =487)						Hispanic Americans (N =1095)
	Men (n = 208)			Women (n=279)			Men (n = 449)			Women (n=646)
	No HTN (n=154)	HTN (n = 54)	p	No HTN (n=205)	HTN (n=74)	P	No HTN (n = 348)	HTN (n=101)	p	No HTN (n = 540)	HTN (n = 106)	p
Age^a	39.1 (1.3)	52.7 (1.5)	<0.001	36.5 (1.1)	53.2 (1.3)	<0.001	37.8 (0.8)	48.1 (10.6)	<0.001	39.4 (0.7)	56.0 (1.5)	<0.001
BMI (kg/m²)^a	27.5 (0.5)	29.8 (0.7)	<0.001	29.0 (0.6)	33.4 (0.8)	<0.001	27.8 (0.4)	30.4 (0.5)	<0.001	28.4 (0.3)	31.0(0.5)	<0.001
Visceral Adipose Tissue (cm²)^a	83.8 (4.7)	136.5 (7.6)	<0.001	67.9 (3.5)	122.2 (6.7)	<0.001	114.3 (3.4)	155.2 (6.4)	<0.001	90.8(2.6)	144.1(5.3)	<0.001
Subcutaneous Adipose Tissue (cm²)^a	235.5 (13.9)	295.7 (21.9)	<0.001	387.8 (18.0)	492.0 (19.2)	<0.001	261.0 (8.6)	310.3 (14.3)	0.002	370.4 (7.9)	422.7 (13.4)	<0.001
VAT/SAT^a	0.39 (0.02)	0.50 (0.03)	<0.001	0.18 (0.01)	0.27 (0.02)	<0.001	0.47 (0.01)	0.56 (0.03)	<0.001	0.25 (0.01)	0.35 (0.01)	<0.001
Waist Circumference (cm)^a	90.40 (1.13)	98.96 (1.84)	<0.001	84.34 (1.22)	97.25 (1.62)	<0.001	92.66 (0.81)	99.49 (1.04)	<0.001	84.52 (0.82)	91.56 (1.07)	<0.001
Waist-to-hip ratio^a	0.86 (0.01)	0.91 (0.01)	<0.001	0.77 (0.01)	0.83 (0.01)	<0.001	0.91 (0.003)	0.95 (0.006)	<0.001	0.79 (0.003)	0.83 (0.006)	0.003
Impaired Fasting
Glucose or Type 2	41 (27)	28 (51.9)	<0.008	26 (12.7)	41 (55.4)	<0.001	81 (23.3)	37 (37.0)	<0.03	77 (14.3)	37 (35.6)	<0.001
Diabetes^b ^†
Type 2 diabetes^b	2 (1.3)	N = 1 (1.8)	0.43^††	2 (1.0)	8 (10.8)	<0.001^††	11 (2.5)	9 (9.0)	0.01	6 (1.1)	4 (3.8)	0.05^††
Insulin Sensitivity (10⁻⁴ × min⁻¹ × μU⁻¹ × ml⁻¹)	1.9 (0.1)	1.1 (0.1)	<0.001	1.7 (0.1)	1.0 (0.1)	<0.001	2.2 (0.1)	1.4 (0.2)	0.007	2.3 (0.1)	1.2 (0.1)	<0.001
Taking antihypertensive medications^b ^c	-	33 (61.1)	-	-	58 (78.4)	-	-	26 (25.7)	-	-	51 (48.1)	-

Data are reported as M (SE)

Data are reported as N (%)

^†

participants with impaired fasting glucose (defined as fasting glucose > 100 mg/dl at clinical examination), or participants with Type 2 diabetes (defined as >126 mg/dl at clinical examination) not taking medication

^††

Fisher's exact test

among participants with hypertension